Faeth Therapeutics (FTH)
NASDAQ:FTH
Want to see FTH full AI Analyst Report?
Top Page
Faeth Therapeutics
(NASDAQ:FTH)
Select Model
Select Model
Rating:45Neutral
Price Target:
$16.00
▲(40.11% Upside)
Action:Reiterated
Date:06/18/26
The score is held down primarily by weak financial performance (no meaningful revenue, ongoing cash burn, and negative TTM equity increasing financing/dilution risk). Technicals are mixed with negative MACD and the stock below key medium-term averages, while valuation is constrained by a loss-making profile and no dividend support.
Positive Factors
Low financial leverage
Low recorded debt reduces interest burden and preserves capital flexibility. Over the next 2–6 months this strengthens the firm's ability to raise non-destrictive financing or pursue partnerships without immediate solvency pressure, supporting runway management during clinical development.
Negative Factors
No meaningful revenue
Absence of product or recurring revenue forces reliance on external funding and partner deals to support operations. Over months this elevates execution risk, ties program progress to financing events, and prevents internal cash generation needed to self-fund trials or scale.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Low recorded debt reduces interest burden and preserves capital flexibility. Over the next 2–6 months this strengthens the firm's ability to raise non-destrictive financing or pursue partnerships without immediate solvency pressure, supporting runway management during clinical development.
Read all positive factors
Faeth Therapeutics (FTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.91M
Dividend YieldN/A
Average Volume (3M)38.93K
Price to Earnings (P/E)―
Beta (1Y)1.77
Revenue GrowthN/A
EPS Growth-518.34%
CountryUS
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-147.90
Shares Outstanding1,341,941
10 Day Avg. Volume109,584
30 Day Avg. Volume38,927
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market Cap-5.39
Enterprise Value/Revenue26.58
Enterprise Value/Gross Profit0.97
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$53.33Price Target Upside367.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-118.07
Revenue Forecast (FY)N/A
Faeth Therapeutics Business Overview & Revenue Model
Company Description
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational a...
How the Company Makes Money
Sensei Biotherapeutics does not have publicly disclosed, recurring revenue from commercial product sales because its programs are in clinical development rather than marketed. As a result, to the extent revenue is reported, it would generally be e...
Faeth Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -4.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -132.96M | 0.00 | -551.00K | -571.00K | -1.81M | -685.00K |
| EBITDA | -184.30M | -20.91M | -29.52M | -33.39M | -46.56M | -35.44M |
| Net Income | -184.46M | -21.09M | -30.16M | -34.10M | -48.59M | -36.79M |
Balance Sheet | ||||||
| Total Assets | 205.38M | 22.90M | 45.36M | 74.37M | 118.38M | 153.22M |
| Cash, Cash Equivalents and Short-Term Investments | 202.79M | 21.18M | 41.34M | 65.76M | 107.12M | 147.62M |
| Total Debt | 1.04M | 1.51M | 3.85M | 6.21M | 8.03M | 2.35M |
| Total Liabilities | 14.19M | 4.31M | 6.97M | 9.48M | 14.97M | 6.71M |
| Stockholders Equity | 191.19M | 18.59M | 38.39M | 64.89M | 103.41M | 146.51M |
Cash Flow | ||||||
| Free Cash Flow | -24.11M | -20.47M | -24.82M | -32.20M | -39.35M | -32.28M |
| Operating Cash Flow | -24.09M | -20.45M | -24.67M | -32.02M | -39.03M | -30.26M |
| Investing Cash Flow | -18.86M | 19.77M | 22.44M | 38.41M | 49.95M | -143.12M |
| Financing Cash Flow | 185.40M | -645.00K | -787.00K | -11.17M | -287.00K | 163.94M |
Faeth Therapeutics Technical Analysis
Positive
11.42
Price Trends
22.11
Negative
23.13
Negative
16.41
Positive
Market Momentum
-1.89
Negative
51.69
Neutral
72.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FTH, the sentiment is Positive. The current price of 11.42 is below the 20-day moving average (MA) of 15.69, below the 50-day MA of 22.11, and below the 200-day MA of 16.41, indicating a neutral trend. The MACD of -1.89 indicates Negative momentum. The RSI at 51.69 is Neutral, neither overbought nor oversold. The STOCH value of 72.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FTH.
Faeth Therapeutics Risk Analysis
Faeth Therapeutics disclosed 82 risk factors in its most recent earnings report. Faeth Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Faeth Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $22.30M | -0.57 | -248.91% | ― | ― | 58.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $23.91M | -0.13 | -83.59% | ― | ― | -518.34% | |
45 Neutral | $13.72M | -1.55 | -94.94% | ― | ― | 53.06% | |
45 Neutral | $10.44M | -0.33 | -423.84% | ― | -8.47% | 25.61% | |
40 Underperform | $7.67M | -0.25 | -97.58% | ― | 78.64% | 50.70% |
* Healthcare Sector Average
FTH
Faeth Therapeutics
17.82
10.16
132.64%
CLRB
Cellectar Biosciences
2.79
-5.96
-68.11%
COCP
Cocrystal Pharma
1.00
-0.50
-33.22%
BRTX
BioRestorative Therapies
0.41
-1.17
-74.11%
BOLT
Bolt Biotherapeutics
3.99
-1.80
-31.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.